SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jun 13, 2019
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: June 13, 2019 · CIK: 0001390478 · Accession: 0001144204-19-030768
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231723
Letter
A.G.P./Alliance Global Partners
590 Madison Avenue, 36th Floor
New York, New York 10022
June 13, 2019
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
Re: SELLAS Life Sciences Group, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-231723)
Ladies and Gentlemen:
In connection with the above-captioned registration statement on form S-1 (the “Registration Statement”), and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representative of the several underwriters, hereby join in the request of the Company that the effective date of the Registration Statement be accelerated to 4:30 p.m. Eastern Time on June 13, 2019, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., may orally request via telephone call that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, the representative of the several underwriters, wish to advise you that there will be distributed to each prospective underwriter, institution or dealer who is reasonably anticipated to participate in the distribution of the securities as many copies of the Company’s preliminary prospectus, dated June 13, 2019, as amended and as included in the Registration Statement, as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We further advise you that we have complied and will continue to comply, and we have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Act.
[Signature Page Follows]
Very truly yours,
A.G.P./Alliance Global
Partners
Show Raw Text
CORRESP
1
filename1.htm
A.G.P./Alliance
Global Partners
590 Madison Avenue, 36th Floor
New York, New York 10022
June 13, 2019
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski
Re:
SELLAS Life Sciences Group, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-231723)
Ladies and Gentlemen:
In connection with
the above-captioned registration statement on form S-1 (the “Registration Statement”), and pursuant to Rule
461 under the Securities Act of 1933, as amended (the “Act”), we, as the representative of the several underwriters,
hereby join in the request of the Company that the effective date of the Registration Statement be accelerated to 4:30 p.m. Eastern
Time on June 13, 2019, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C., may orally request via telephone call that such Registration Statement be declared
effective.
Pursuant to Rule 460
under the Act, we, the representative of the several underwriters, wish to advise you that there will be distributed to each prospective
underwriter, institution or dealer who is reasonably anticipated to participate in the distribution of the securities as many copies
of the Company’s preliminary prospectus, dated June 13, 2019, as amended and as included in the Registration Statement, as
appears to be reasonable to secure adequate distribution of the preliminary prospectus. We further advise you that we have complied
and will continue to comply, and we have been informed by the participating underwriters and dealers that they have complied with
and will continue to comply, with the requirements of Rule 15c2-8 under the Act.
[Signature Page Follows]
Very truly yours,
A.G.P./Alliance Global
Partners
As the Representative of the Underwriters
By:
/s/ Thomas J. Higgins
Name:
Thomas J. Higgins
Title:
Managing Director